Everolimus - Overview, Indication, Side Effects, and Pharmacology

What Is the Role of Everolimus in Advanced Renal Cell Carcinoma?

Renal Cell Carcinoma (RCC) is a type of kidney cancer that originates in the lining of the small tubes within the kidney. It is known for its resistance to traditional chemotherapy, so searching for effective targeted therapies is crucial. Everolimus, a mammalian rapamycin (mTOR) inhibitor target, has emerged as a promising drug in treating advanced RCC. Everolimus was first approved by the United States Food and Drug Administration (FDA) for the treatment of advanced renal cell carcinoma (RCC) on March 30, 2009.

Drug Group:

Everolimus belongs to a class of drugs known as mammalian targets of rapamycin (mTOR) inhibitors. The mTOR pathway is crucial in cellular growth, proliferation, and angiogenesis.

Available Doses and Dosage Forms:

Everolimus is commonly available in tablet form, and the available strengths may include:

Tablets:

• 2.5 mg (milligrams).

• 5 mg.

• 10 mg.

For Patients:

How Does Everolimus Work?

• Everolimus is a blocker of mTOR (rapamycin's mammalian target).

• The mTOR signaling pathway, which regulates cell division and proliferation, is blocked.

• Angiogenesis, or the development of new blood vessels, is similarly influenced by the mTOR pathway.

• Cancers such as renal cell carcinoma (RCC) frequently have an overactive RCC pathway.

• Everolimus inhibits mTORC1, which limits the growth and spread of cancer cells.

• This slows tumor growth.

How Effective Is Everolimus?

The type of cancer and each patient's characteristics determine how effective Everolimus is.

• Neuroendocrine tumors and advanced renal cell carcinoma (RCC) have both benefited from it.

• Overall survival and progression-free survival (PFS) are often used metrics to assess its effectiveness.

• According to clinical research, Everolimus increases PFS in RCC, particularly when tyrosine kinase inhibitors don't work.

• Because each patient responds differently to treatment, no two people will experience the same outcomes.

• The cancer specialists decide whether to use Everolimus depending on the patient's health, past medical history, and the features of the malignancy.

What Are the Things to Inform the Doctor Before Taking the Drug?

• If you have any known drug or substance allergies, let the doctor know.

• Describe any current medical issues you may have, particularly liver or kidney illness.

• Mention any past infections.

• List all of your current prescription meds, including over-the-counter medications, vitamins, and supplements.

• Because Everolimus can harm the fetus, let the doctor know if you are pregnant, planning to become pregnant, or nursing.

• Talk about past cancer treatments, including radiation, chemotherapy, or targeted therapy.

• Examine past immunization records, as certain vaccines may be prohibited during treatment.

• Everolimus may affect reproductive health; discuss any fertility-related issues.

How Is Everolimus Administered?

• Everolimus is available as an oral tablet.

• Taking it with or without food is possible.

• It is recommended to swallow tablets whole with water.

• Avoid chewing or crushing the tablet.

• Observe the precise dosage and timing that the doctor has prescribed.

What Are the Side Effects of Everolimus?

• Stomatitis (mouth sores).

• Rash.

• Fatigue.

• Diarrhea.

• Infections.

• Anemia.

• Hyperglycemia (elevated blood sugar).

• Elevated liver enzymes.

• Interstitial lung disease (rare).

• Poor wound healing.

Dietary Considerations:

While taking Everolimus, follow the dietary and nutritional advice your doctor gives you, such as:

• To stay healthy and happy, eat a healthy, well-balanced diet.

• If you have stomach problems like stomatitis or mouth sores, eat foods that are softer or easier to digest.

• To be well hydrated, make sure you drink enough fluids.

• Talk to your healthcare team about any dietary issues or restrictions to make sure you get the nutrients you need while taking Everolimus.

Missed Dose:

• If you forget to take a dose of Everolimus, do as your doctor says.

• If you missed a dose, don't take two doses at once to make up for it.

• If you remember to take the missed dose within the time window your healthcare practitioner specified, do so. If not, wait for the next scheduled dose.

• To get the best results from your treatment, always take Everolimus as directed.

• If you have any questions about missed doses, contact the healthcare staff right away to avoid changes to the treatment plan.

Overdose:

If you think you have taken too much Everolimus, get medical help right away.

• Watch for major side effects, such as common side effects worsening or signs of a serious allergic reaction.

• If you think someone has overdosed, call emergency services right away.

• Before changing the dose, talk to a doctor or other health care expert.

• If you think you might have taken too much, tell the healthcare professionals so they can help you.

Storage

How to Store It?

• To keep Everolimus strong and stable, keep it in its original container.

• Control the temperature: Keep it at ambient temperature, away from too much heat or moisture.

• Stay away from places with high humidity, such as the kitchen or bathroom, where temperatures and humidity can change.

• Safety: Keep out of reach of kids and pets.

• Follow the advice of professionals: Follow any additional storage recommendations from your pharmacist or healthcare provider.

• If you have any questions about how to store the medicine or if it looks different than you expected, call a pharmacist or another healthcare professional.

For Doctors:

Dosage:

• Advanced Renal Cell Carcinoma (RCC): 10 mg orally once daily.

• Pancreatic Neuroendocrine Tumors (PNET): The recommended dose is usually 10 mg orally once daily.

• Subependymal Giant Cell Astrocytoma (SEGA) Associated with Tuberous Sclerosis: The dose is based on body surface area and is usually in the range of 4.5 mg/m² (milligram per meter square) to 7.5 mg/m², taken orally once daily.

• Breast Cancer (In Combination With Exemestane): The recommended dose is typically 10 mg orally once daily.

Dosing Considerations:

• Depending on the patient's tolerance and adverse effects, the dosage may change.

• Dosage modifications may be necessary for patients with liver or renal impairment.

• The right dosage is decided by the healthcare professional on an individual basis.

• The safety or effectiveness of everolimus may be impacted by interactions with other medicines.

• All over-the-counter, prescription, and supplement medications must be declared.

• Blood counts, as well as liver, kidney, and blood sugar testing, must be performed regularly.

What Are the Pharmacological Aspects of Everolimus?

Pharmacodynamics:

• mTOR Inhibition: Everolimus is an mTOR inhibitor that works on the mTORC1 complex. mTOR is an important regulator of cell growth, proliferation, and survival. Everolimus blocks mTORC1, disrupting signaling pathways within cells and slowing protein synthesis and the cell cycle.

• Anti-Angiogenic Effects: Everolimus inhibits angiogenesis by blocking the formation of new blood vessels. This is especially important for treating some types of cancer, such as renal cell carcinoma, because angiogenesis is a key aspect of how tumors grow.

• Immunosuppression: Everolimus reduces your immune response, which helps prevent organ rejection after a transplant. It stops T-lymphocytes from responding to interleukin-2, a cytokine that helps activate immune cells.

• Cell Cycle Arrest: It blocks mTOR, preventing cells from progressing through the cell cycle. This stops the unregulated cell division that helps in tumor proliferation.

Mechanism:

• Everolimus acts by blocking the mammalian target of rapamycin (mTOR) pathway that regulates cell growth and proliferation.

• Everolimus selectively targets mTOR complex 1 (mTORC1) as an mTOR inhibitor, which disrupts intracellular signaling pathways.

• Everolimus has anti-angiogenic properties that hinder the formation of new blood vessels essential for tumor growth and promote cell cycle arrest, which prevents cells from progressing through the cell cycle.

• Furthermore, T-lymphocyte activation is modulated by its immunosuppressive actions.

Overall, Everolimus is a useful therapeutic drug in various medical settings, such as treating certain malignancies and preventing organ rejection in transplant patients, thanks to its complex mechanism of action.

Pharmacokinetics:

• Everolimus is an orally administered macrolide with antitumor and immunosuppressive effects. Its pharmacokinetic processes are thoroughly studied. Everolimus is absorbed in the gastrointestinal tract after oral administration, and food intake affects this process. The medication has a high volume of distribution, suggesting extensive tissue distribution.

• Everolimus is mostly metabolized in the liver. The cytochrome P450 enzyme system, especially CYP3A4, helps it break down completely there. Even though several metabolites have formed, the parent drug remains the main compound circulating.

• Excretion is mainly through the feces, with a small amount via urine. The comparatively lengthy elimination half-life supports the use of a single daily dose.

• Patients suffering from hepatic impairment should be given extra concern since their medication may require dose modifications due to changes in drug metabolism. Everolimus clearance is not significantly affected by renal impairment. However, modifications should be considered depending on a patient's unique circumstances.

Clinical Studies:

Everolimus's safety and efficacy have been established by clinical trials, including the RECORD (Renal Cell Cancer Therapy with Oral RAD001 Administered Daily) trials. Breast cancer, pancreatic neuroendocrine tumors (PNET), and advanced renal cell carcinoma (RCC) have been among the indications that have been the focus of these trials. These trials' findings have shown that, in some patient groups, Everolimus can effectively extend progression-free survival. The trials have also shed light on the medication's safety profile, helping medical professionals weigh the advantages and disadvantages of Everolimus when treating a specific patient.

What Are the Contraindications of Everolimus?

• Known drug hypersensitivity or its components.

• During pregnancy, it has the potential to harm a developing fetus. Both men and women should take appropriate contraceptive measures during and after treatment.

• Breastfeeding.

• Hepatic impairment.

Warnings and Precautions:

• Infections, including bacterial, viral, and fungal infections, can become more likely when taking Everolimus. Patients should be monitored for signs of infection, and therapy may need to be stopped if a serious infection develops.

• Pneumonitis, which is not contagious and is typified by lung tissue inflammation, has been linked to Everolimus. Patients should be monitored for respiratory symptoms, and medication may need to be modified if pneumonitis is detected.

• Everolimus has been linked to cases of renal failure, particularly acute renal failure. Patients with reduced renal function may need to adjust their dosages, and their renal function should be closely checked.

• Hyperglycemia and hyperlipidemia are two metabolic diseases that Everolimus may bring on. It is important to monitor blood glucose and cholesterol levels and to implement appropriate management techniques.

• Everolimus may delay wound healing. Patients with non-healing wounds or undergoing surgery should be treated cautiously.

• There have been reports of angioedema, a severe allergic response including swelling of the skin's deeper layers. Patients should be kept an eye out for any indications of angioedema, and medication should be stopped immediately if they do.

• Anaphylaxis and other hypersensitivity events have been documented. In the event of a severe hypersensitivity response, Everolimus should be stopped.

• Everolimus may hamper both male and female fertility. It is advised to use effective contraception both during and after therapy. Because pregnancy during Everolimus therapy might damage the fetus, it should be avoided.

What Are the Drug Interactions of Everolimus?

• Strong CYP3A4 inhibitors, such as Ketoconazole, Itraconazole, and Clarithromycin, can greatly raise Everolimus blood levels, which raises the risk of toxicity. Careful monitoring and dose reduction may be necessary.

• Rifampin, Phenytoin, and Carbamazepine are strong CYP3A4 inducers that can drop Everolimus blood levels. This could make it less effective, so you may need to change the dose or try a different treatment.

• Everolimus can change the way other drugs that are broken down by CYP3A4 work, raising their blood levels and the chance of side effects. It's best to keep a close eye on these drugs and possibly change their doses.

• During Everolimus therapy, live immunizations should be avoided because immunosuppression may increase the risk of severe infections or diminish vaccine safety.

Specific Considerations:

• Hepatic Impairment: Be cautious when using Everolimus, as the liver breaks it down. Depending on the severity of the liver malfunction, the dose may need to be adjusted. It is also very important to monitor liver function regularly.

• Renal Impairment: Everolimus is primarily eliminated in the feces; patients with kidney problems should be closely monitored. It may be necessary to check kidney function and adjust the dose if needed.

• Pediatric Use: Everolimus is licensed for several pediatric conditions, including subependymal giant cell astrocytoma (SEGA), a condition associated with tuberous sclerosis. The dose depends on the person's body surface area, and they need to be closely watched in a clinical setting.

• Geriatric Use: Older people may metabolize drugs differently and be more sensitive to side effects. It is important to closely monitor liver and kidney function and consider adjusting the dose based on each patient's needs.

• Pregnancy: Everolimus may harm the fetus; it should not be taken during pregnancy. Both men and women need to use effective birth control while they are getting treatment, and women who could get pregnant should have a pregnancy test before starting medication.

• Breastfeeding: You shouldn't breastfeed while taking Everolimus, as it could harm the baby.

• Clinical Monitoring: It is important to regularly monitor lipid profile, blood glucose, liver and kidney function, and full blood counts. You should let your doctor know right away if you notice any strange side effects, breathing problems, or signs of infection.

• Patient Education: Patients should know how important it is to follow the doctor's instructions about the dose and schedule, be aware of any side effects, and tell their doctor right away if they have any symptoms that worry them.